Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Editorial

Letter regarding Wang et al. entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis”

Authors: Guoyan Liu, Wanli Xu, Yanke Hao, Zhanwang Xu

Published in: Tumor Biology | Issue 4/2014

Login to get access

Excerpt

To the Editor, …
Literature
1.
Wang LC, Liu ZH, Jing PW, Shao L, Chen L, He X, et al. Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol. 2013. doi:10.​1007/​s13277-013-1227-8.
2.
Xu J, Turner A, Little J, Bleecker ER, Meyers DA. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet. 2002;111(6):573–4.PubMedCrossRef
3.
Ziegler A, Van Steen K, Wellek S. Investigating Hardy-Weinberg equilibrium in case–control or cohort studies or meta-analysis. Breast Cancer Res Treat. 2011;128(1):197–201.PubMedCrossRef
Metadata
Title
Letter regarding Wang et al. entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis”
Authors
Guoyan Liu
Wanli Xu
Yanke Hao
Zhanwang Xu
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1505-5

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis

Research Article

Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies

Research Article

Study of circulating antibodies against CD25 and FOXP3 in breast cancer

Research Commentary

Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press

Research Article

Common genetic variants at 1q22 and 10q23 and gastric cancer susceptibility in a Korean population

Research Article

Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits